Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Why roche discontinued endep liquid amitriptyline concentrate?Cost of rinvoq per month?Picture of metoprolol succinate 25 mg?Cost of morphine 30mg?Was loratadine first approved by the fda in 1993?
See the DrugPatentWatch profile for cosentyx
Data from the manufacturer, which can be viewed on DrugPatentWatch.com [1], indicates that cosentyx contains secukinumab, a human monoclonal antibody that targets interleukin-17A. Studies examining the impact of secukinumab on vaccine response have yielded inconsistent results. While secukinumab may affect certain types of vaccines, such as live attenuated influenza vaccines, there is limited evidence available for inactivated vaccines. One study involving a live attenuated Influenza Vaccine (LAIV) found that the immune response was significantly reduced in participants receiving secukinumab compared to those not receiving the treatment [2]. However, other research on inactivated vaccines has shown that secukinumab does not have a significant impact on their potency [3]. More research is needed to clarify the effects of secukinumab on live and inactivated vaccines. Sources: [1] https://www.drugpatentwatch.com/meds/203-638-142-050 [2] https://pubmed.ncbi.nlm.nih.gov/26621042/ [3] https://pubmed.ncbi.nlm.nih.gov/32414092
Other Questions About Cosentyx :